###### Key questions

What is already known about this subject?
=========================================

The role of microRNAs (miRNAs) in patients with coronary artery calcification (CAC) has not been examined.

What does this study add?
=========================

We have identified miRNA 8059 to be significantly downregulated in patients with extensive CAC.

How might this impact on clinical practice?
===========================================

miRNA 8059 may serve as a novel biomarker for the presence and extent of CAC, as well as provide a platform to study the molecular mechanism underpinning vascular calcification.

Background {#s1}
==========

Atherosclerotic coronary artery disease (CAD) remains the most common cause of morbidity and mortality in the Western world.[@R1] In approximately 50% of individuals, the initial presentation of CAD is a myocardial infarction or sudden cardiac death. As a consequence, international guidelines such as the American Heart Association and the European Society of Cardiology have recommended the use of screening tests to identify high-risk individuals.[@R2] However, conventional clinic-based models such as the Framingham Risk Score, which creates three categories of 10-year risk for a future cardiovascular event, can only predict 60%--65% of individuals at risk of a cardiovascular event, and are therefore unable to identify many individuals who go on to have an acute cardiac event.[@R4] Recent studies have focused on the assessment of the degree of coronary artery calcification (CAC) as a risk assessment tool for cardiovascular events. The clinical utility of coronary CT for the assessment of CAC and the presence of obstructive CAD has been well validated, but its applicability may be limited by cost, poor image quality in patients with obesity and its relative contraindication in patients with renal impairment and contrast allergy.[@R5] MicroRNAs (miRNAs) are short, non-coding RNAs that regulate gene expression by annealing to partially complementary sites on the 3' untranslated region of messenger RNA (mRNA) to suppress their translation.[@R9] A number of studies have demonstrated the clinical utility of miRNAs in the diagnosis and prognosis of a number of cardiovascular disorders such as myocardial infarction, stable angina and heart failure.[@R10] Furthermore, recent studies have also identified miRNAs to play a role in arterial calcification; for example, miRNA-204 and miRNA-125b have been implicated in vascular smooth muscle calcification in in vitro models.[@R13] As a consequence, identification of an 'miRNA signature' that is characteristic of CAC may represent a novel, safe and non-invasive approach in the diagnosis of patients with CAC.

This study was designed to determine whether human blood-based miRNAs could represent plausible biomarkers for the presence and extent of CAC in patients with isolated CAC (defined as CAC in the absence of an underlying metabolic abnormality known to be associated with CAC), which could then be used as a platform to study the molecular mechanism(s) responsible for isolated CAC.

Methods {#s2}
=======

Patients {#s2a}
--------

The miRNAs as Potential Biomarkers for Coronary Artery Calcification (MAP-Calcification) was a prospective study registered at ClinicalTrials.gov (NCT01992848). All participants gave informed consent before enrolment. Twenty-four patients who were matched for sex, age, hypertension and smoking history undergoing elective CT calcium scoring and coronary angiography as part of routine clinical investigation for cardiac chest pain were prospectively recruited. Clinical inclusion criteria were age ≥18 years and ability to provide written informed consent. Exclusion criteria were age \>65 years, diabetes mellitus, glomerular filtration rate ≤60 mL/min, abnormal serum calcium, history or clinical features of cardiac failure, valvular heart disease, previously documented CAD, history of coronary revascularisation, history of cerebrovascular disease, peripheral vascular disease, systemic inflammatory disease, active infection and active malignancy.

CT coronary calcium scoring {#s2b}
---------------------------

Coronary artery calcium scores (CACS) were obtained using a General Electric (GE) VCT XTe 64-slice CT scanner. All patients had an unenhanced cardiac-gated calcium score calculated using the GE Advantage Workstation 4.4 with the default software. An optimal heart rate (aiming for \<60 beats/min) was achieved with the administration of variable doses of metoprolol. Of the 150 mL of Niopam 370 contrast, 150  mL were injected at 6 mL/s, followed by 50 mL of normal saline solution at 6 mL/s. Subsequent CT coronary angiography was performed with prospective cardiac-gated acquisition.

Blood collection and analysis {#s2c}
-----------------------------

Venous blood samples were drawn via antecubital venepuncture. Routine haematology and biochemistry were assessed in plasma. An aliquot of whole blood (10 mL) for each subject was collected and total RNA isolated using the LeukoLOCK Total RNA Isolation System with DNase treatment, following manufacturer's instructions (Thermo Fisher Scientific, Warrington, UK). Total RNA quantity and quality were determined using a NanoDrop Technologies ND-1000 spectrophotometer and an Agilent 2100 Bioanalyzer. All samples had an RNA integrity number greater than 7. Toray microarray analysis of all the known human miRNAs and the relevant bioinformatics analysis of the 24 patients were undertaken at the Cambridge Genomic Centre, UK.

Quantitative reverse transcription PCR (qRT-PCR) of four miRNAs (miRNA-8059, miRNA-138-2 and miRNA-1181) that were identified on bioinformatic analysis of the microarray data was performed using the Qiagen miScript system, following manufacturer's instructions (Qiagen, Crawley, UK). Briefly, total RNA (250 ng) underwent reverse transcription using the miScript II RT Kit with HiSpec Buffer to convert the mature miRNAs into complementary DNA. Specific miRNAs were purified using the SYBR Green PCR Kit with specific miScript primer assays. The cycle parameters were 95°C for 15 min, followed by 40 cycles of 95° C for 15 s, 55° C for 30 s and 70° C for 35 s. All samples were analysed in duplicates. The geometric mean of RNU-6 and SNORD 61 was used to normalise the miRNA expression data. There was an agreement between qRT-PCR values and a mean value of duplicates was used. The coefficient of variation of the qRT-PCR assay was \<10%. Pathway analysis for the mRNA targets for the differentially expressed miRNAs was carried out using DIANA-miRPath V.3 in order to determine the possible signalling cascades that the identified miRNAs may be regulating.[@R15]

Statistical analysis {#s2d}
--------------------

A formal power calculation was not undertaken as this was a proof-of-concept study. Statistical analysis was performed using SAS V.8.2. Continuous variables and categorical variables are expressed as mean±SD, number of patients and percentages, respectively. Clinical demographics, CT variables, microarray and qRT-PCR data were analysed using a one-way analysis of variance or two-tailed unpaired t-test with Welch correction as appropriate. A P value \<0.05 was considered statistically significant.

Results {#s3}
=======

The patients were divided into four groups based on their calcium score in order to determine whether differences in miRNA were attributable to subtle differences in the CACS: CACS=0, CACS=1--10, CACS=11--100 and CACS \>100. The four groups of patients were well matched for age, sex, body mass index, hypertension, dyslipidaemia, current smoking habit and family history for CAD ([table 1](#T1){ref-type="table"}). The patients also had similar haemoglobin, creatinine, total cholesterol and triglyceride, glucose, and corrected calcium concentrations ([table 1](#T1){ref-type="table"}). There were differences in the medical therapy across the four groups of patients ([table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics of the patients

  Variable                       CAC=0 (n=6)   CAC=1--10 (n=6)   CAC=11--100 (n=6)   CAC\>100 (n=6)   P value
  ------------------------------ ------------- ----------------- ------------------- ---------------- ---------
  Age (years)                    55.7±5.8      51.3±9.0          53.4±7.9            54.0±6.4         0.80
  Male sex                       4 (66.7%)     3 (50%)           4 (66.7%)           5 (83.3%)        0.70
  BMI (kg/m^2^)                  24.8±4.3      25.1±2.3          27.6±4.8            25.3±2.2         0.69
  Hypertension                   3 (50%)       2 (33.3%)         2 (33.3%)           1 (16.7%)        0.70
  Dyslipidaemia                  1 (16.7%)     1 (16.7%)         2 (33.3%)           3 (50%)          0.55
  Current smokers                4 (66.7%)     2 (33.3%)         2 (33.3%)           3 (50%)          0.73
  FHx for CAD                    0 (0%)        3 (50%)           3 (50%)             3 (50%)          0.20
  Haemoglobin (g/L)              14.6±0.89     14.4±1.4          15.3±1.1            15.3±1.4         0.35
  Creatinine (µmol/L)            74.7±17.7     74.8±15.1         73.2±8.5            78.2±7.0         0.86
  Total cholesterol (mmol/L)     5.5±0.70      5.0±0.8           5.6±0.7             5.7±1.1          0.45
  Triglycerides (mmol/L)         1.1±0.3       1.2±0.6           1.8±0.8             1.8±1.1          0.19
  Glucose (mmol/L)               5.0±1.5       4.9±0.6           5.0±0.4             5.2±0.4          0.94
  Corrected calcium (mmol/L)     2.2±0.1       2.2±0.1           2.3±0.1             2.3±0.0          0.09
  Medication                                                                                          
   Calcium channel antagonists   2 (33.3%)     2 (33.3%)         0 (0%)              0 (0%)           0.21
   ACE inhibitors                1 (16.7%)     0 (0%)            0 (0%)              1 (16.7%)        0.67
   Statins                       0 (0%)        0 (0%)            0 (0%)              2 (33.3%)        0.89
   Aspirin                       0 (0%)        0 (0%)            0 (0%)              2 (33.3%)        0.89
   Diuretics                     0 (0%)        0 (0%)            1 (16.7%)           0 (0%)           0.41

BMI, body mass index; CAC, coronary calcium score; CAD, coronary artery disease; FHx, family history.

The mean calcium score was 1.7±1.0 in patients with CACS=1--10, 39.5±29.7 in patients with CACS=11--100, and 278±20.5 in patients with CACS\>100 ([table 2](#T2){ref-type="table"}). The number of diseased vessels was 0.2±0.4 in patients with CACS=1--10, 0.3±0.5 in patients with CACS=11--100, and 2.2±1.3 in patients with CACS\>100 ([table 2](#T2){ref-type="table"}).

###### 

CT-derived data for the four cohorts of patients

  Variable      Calcium score    Percentile for age   Number of diseased vessels
  ------------- ---------------- -------------------- ----------------------------
  CAC=0         Not Applicable   Not Applicable       Not Applicable
  CAC=1--10     1.7±1.0          50±28.6              0.2±0.4
  CAC=11--100   39.5±29.7        54.7±29.9            0.3±0.5
  CAC\>100      278±20.5         83.7±17              2.2±1.3

CAC, coronary calcium score.

Toray microarray analysis of the known human miRNAs and subsequent bioinformatics analysis of the generated data indicated significant downregulation of miRNAs 138-2-3p, 1181, 6816 and 8059 in patients with CACS\>100 as compared with patients with CAC=0 ([figures 1 and 2](#F1 F2){ref-type="fig"}). qRT-PCR analysis confirmed significant downregulation of only miRNA-8059 in patients with CACS\>100 ([figure 3](#F3){ref-type="fig"}). Pathway analysis was carried out using the online tool DIANA Tools miRPath, and this identified the mRNA pathways targeted by miRNA-8059[@R15] ([table 3](#T3){ref-type="table"}).

![Toray microarray analysis of the four groups of patients (A) and in patients with calcium score \>100 (B). These data indicate that the expression of four microRNAs is significantly reduced in patients with calcium score \>100 compared with controls: miRNA-138-2-3p, miRNA-1181, miRNA-6816-3p and miRNA-8059. Data are presented as mean±SEM. Ca, calcium.](openhrt-2017-000678f01){#F1}

![Heat map of microRNA microarray expression from the four groups of patients. The expression range 'low-moderate-high' is indicated by the colour range 'blue-white-red'. The upper colour bar represents the groups as follows: yellow for CACS=0, green for CACS=1--10, red for CACS=11--100 and blue for CACS\>100. CACS, coronary artery calcium score.](openhrt-2017-000678f02){#F2}

![Quantitative reverse transcription PCR analysis indicated significant downregulation of miR-8059 in patients with coronary artery calcification score\>100 (P=0.03). Ca, calcium.](openhrt-2017-000678f03){#F3}

###### 

Gene pathways predicted to be regulated by miRNA-8059

  KEGG pathway                                     P value    Genes (n)   miRNAs (n)
  ------------------------------------------------ ---------- ----------- ------------
  Metabolism of xenobiotics by cytochrome P450     1.34E-20   2           1
  Biosynthesis of unsaturated fatty acids          6.66E-11   1           1
  Fatty acid metabolism                            3.44E-06   2           1
  Chemical carcinogenesis                          0.0023     2           1
  Glycosaminoglycan biosynthesis-keratan sulfate   0.0034     1           1
  Glycosaminoglycan degradation                    0.013      1           1
  Nucleotide excision repair                       0.013      2           1
  Glycosphingolipid biosynthesis                   0.015      2           1
  Proteoglycans in cancer                          0.018      3           1

KEGG, Kyoto encyclopedia of genes and genomes.

Discussion {#s4}
==========

In this study, we investigated the association between peripheral circulating miRNAs and extent of CAC in patients with isolated CAC. Expression profiling identified downregulation of four miRNAs, with miRNA-8059 being validated using qRT-PCR. Specifically, miRNA-8059 was shown to be significantly downregulated in patients with CAC\>100. Our results suggest that miRNA-8059 has the potential to serve as blood-based biomarker for the presence and extent of CAC.

Recent studies have focused on the assessment of the degree of CAC as a robust risk assessment tool. CAC has indeed been shown to be an independent predictor of mortality, in a multivariate model controlling for age, sex, ethnicity and cardiac risk factors.[@R16] Risk-adjusted relative risk ratios for CAC were 2.2-fold, 4.5-fold, 6.4-fold, 9.2-fold, 10.4-fold and 12.5-fold for scores of 11--100, 101--299, 300--399, 400--699, 700--999 and \>1000 when compared with a score of 0. Although vascular calcification is most commonly associated with chronic kidney disease and diabetes mellitus, CAC may occur in isolation in patients with coronary atherosclerosis. The close correlation between the extent of CAC and the atherosclerotic burden has been confirmed by histopathological and intravascular studies so that the CACS, as measured by CT coronary angiography, has been established as an anatomical surrogate of overall cardiac plaque burden.[@R17] CT coronary angiography is, however, of limited use as a screening modality due to its availability, cost and radiation exposure.

miRNAs have emerged as robust diagnostic and prognostic markers in a wide range of clinical conditions ranging from oncology, immunology and cardiovascular disorders.[@R19] The mechanism(s) underlying isolated CAC remains largely elusive. It is established that chronic inflammation within the plaque microenvironment is an important factor in the pathogenesis of coronary calcification. Specifically, for example, macrophages, lymphocytes and dendritic cells within the plaque secrete cytokines such as tumour necrosis factor that can activate the Msx2-Wnt signalling leading to augmentation of nuclear ß-catenin accumulation and osteogenic differentiation.[@R21] The pro-oxidant, H~2~O~2~, has also been shown to promote osteochondrocytic differentiation of vascular smooth muscle cells through upregulation of the osteogenic transcription factor Runx2.[@R22] Products of lipid peroxidation such as oxidised-LDL (low density lipoprotein) also induce osteogenic-mediated and apoptosis-mediated calcifications of vascular cells.[@R23] Calcification may also be induced by a variety of metabolic factors such as pyrophosphate and urate crystals, vitamin D, as well as glucose.[@R24] miRNA-8059 has been implicated in the regulation of many of the genes that contribute to the above processes, including Uridine diphosphate-N-acetylglucoeamine (UDP-GLCNAc), involved in lymphocyte trafficking; vitamin D receptor, bone morphogenetic protein receptor, involved in bone and cartilage formation; apolipoprotein L, involved in cholesterol transport; and mitochondrial calcium uptake 1, which prevents mitochondrial calcium overload, thus suppressing the production of reactive oxygen species. Given the diverse influence of miRNA-8059 on such pathways, we speculate that miRNA-8059 may represent a novel blood-based biomarker for the presence of CAC, as well as provide a platform for studying the potential mechanism(s) that may underline CAC.

The role of miRNAs in human CAC has not been thoroughly investigated. Liu *et al* [@R25] analysed plasma miRNA levels of 11 patients with CACS\>100 and 6 matched patients with CACS=0 and demonstrated eight miRNAs (223, 3135b, 133a-3p, 2861, 134, 191-3p, 3679-5p, 1229) that were significantly increased in patients with CAC and four miRNAs (2861, 134, 1229 and 3135b) that were correlated with the degree of CAC. A number of significant differences may account for the variations between our results and those of Liu *et al*. First, the focus of our study was on isolated CAC, and for this reason we had devised a strict exclusion criteria excluding, among others, patients with diabetes mellitus, peripheral vascular disease and metabolic abnormalities known to be associated with CAC. By contrast, Liu *et al* had much broader inclusion criteria, including 23.4% of their population being non-insulin-requiring patients with diabetes. Second, we studied miRNAs in the leucocyte population as opposed to the plasma, which may have accounted for the observed differences. Finally, whether ethnic variations (Caucasian vs Chinese) have any impact on miRNA expression has not been previously addressed.

This study has several limitations. We isolated miRNAs from peripheral leucocytes rather than microvesicles, which are known to contain the vast majority of miRNAs, and this may have influenced our results. Furthermore, we have not correlated whether systemic alterations in the expression of miRNA-8059 are associated with similar alterations at the level of coronary arteries.

In conclusion, miRNA-8059 is downregulated in the blood of patients with CACS\>100 and may serve as a biomarker for the presence of isolated CAC, as well as provide a platform to study the underlying pathophysiology of CAC.
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